Cornelis Kluft
#121,610
Most Influential Person Now
Cornelis Kluft's AcademicInfluence.com Rankings
Cornelis Kluftbiology Degrees
Biology
#7403
World Rank
#10323
Historical Rank
Molecular Biology
#855
World Rank
#878
Historical Rank
Biochemistry
#1022
World Rank
#1135
Historical Rank
Download Badge
Chemistry Biology
Cornelis Kluft's Degrees
- PhD Biochemistry University of Amsterdam
- Masters Chemistry University of Amsterdam
Why Is Cornelis Kluft Influential?
(Suggest an Edit or Addition)Cornelis Kluft's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Plasminogen activator inhibitors. (1987) (1062)
- A Simple, Sensitive Spectrophotometric Assay for Extrinsic (Tissue-Type) Plasminogen Activator Applicable to Measurements in Plasma (1982) (563)
- Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. (1988) (464)
- Evidence for the Occurrence of a Fast-Acting Inhibitor for Tissue-Type Plasminogen Activator in Human Plasma (1984) (409)
- The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. (1985) (324)
- Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. (1998) (307)
- Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. (2004) (295)
- Association of depressive disorders, depression characteristics and antidepressant medication with inflammation (2012) (290)
- Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. (1993) (274)
- Effect of moderate dose of alcohol with evening meal on fibrinolytic factors (1994) (263)
- The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. (1993) (239)
- Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study (2002) (225)
- The Adult Netherlands Twin Register: Twenty-Five Years of Survey and Biological Data Collection (2013) (222)
- Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM (1997) (214)
- Daytime Fluctuations in Blood of Tissue-Type Plasminogen Activator (t-PA) and Its Fast-Acting Inhibitor (PAI-1) (1988) (197)
- Effect of Oral Contraceptives on Haemostasis Variables (1997) (186)
- Angiotensin II Increases Plasminogen Activator Inhibitor Type 1 and Tissue‐Type Plasminogen Activator Messenger RNA in Cultured Rat Aortic Smooth Muscle Cells (1994) (183)
- Genome-wide association of major depression: description of samples for the GAIN Major Depressive Disorder Study: NTR and NESDA biobank projects (2008) (181)
- Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. (1999) (166)
- Circadian variation of fibrinolytic activity in blood. (1991) (161)
- Fibrin clot formation and lysis: basic mechanisms. (2000) (159)
- Role of the contact system in fibrinolysis. (1987) (156)
- −455G/A Polymorphism of the β-Fibrinogen Gene is Associated With the Progression of Coronary Atherosclerosis in Symptomatic Men (1998) (152)
- Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. (2003) (147)
- Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. (1996) (138)
- Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study. (1997) (138)
- Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. (1996) (135)
- Reduced Response to Activated Protein C Is Associated with Increased Risk for Cerebrovascular Disease (1996) (134)
- Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. (1990) (127)
- A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. (1991) (117)
- Variable Hypocoagulant Effect of Fish Oil Intake in Humans: Modulation of Fibrinogen Level and Thrombin Generation (2004) (111)
- Intake of n-3 fatty acids from fish does not lower serum concentrations of C-reactive protein in healthy subjects (2004) (107)
- Consumption of black and green tea has no effect on inflammation, haemostasis and endothelial markers in smoking healthy individuals (2000) (100)
- Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus (1995) (100)
- Comparison of Three Isolation Techniques for Human Peripheral Blood Mononuclear Cells: Cell Recovery and Viability, Population Composition, and Cell Functionality. (2016) (96)
- Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. (1999) (94)
- Elevated plasma fibrinogen: cause or consequence of cardiovascular disease? (1998) (94)
- Fibrinolytic shut‐down after surgery: impairment of the balance between tissue‐type plasminogen activator and its specific inhibitor (1985) (93)
- Seasonal Variation in Fibrinogen in the Rotterdam Study (1997) (93)
- The preparation of tissue-type Plasminogen Activator (t-PA) containing liposomes: entrapment efficiency and ultracentrifugation damage. (1995) (93)
- LEIDEN FIBRINOLYSIS WORKING PARTY: BLOOD COLLECTION AND HANDLING PROCEDURES FOR ASSESSMENT OF TISSUE-TYPE PLASMINOGEN ACTIVATOR (t-PA) AND PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1). (1990) (92)
- Progress in fibrinolysis (1981) (87)
- On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction. (2009) (86)
- 4G/4G Genotype of PAI-1 Gene Is Associated With Reduced Risk of Stroke in Elderly (2003) (86)
- A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. (1982) (86)
- Thrombolytic Treatment with Tissue-type Plasminogen Activator (t-PA) Containing Liposomes in Rabbits: a Comparison with Free t-PA (1995) (84)
- Determinants of C-reactive protein concentration in blood. (2001) (82)
- CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone. (1998) (81)
- Liver Blood Flow as a Major Determinant of the Clearance of Recombinant Human Tissue-Type Plasminogen Activator (1992) (81)
- Effect of Chronic Smoking on Fibrinolysis (1985) (80)
- Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. (2002) (79)
- Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels (2001) (78)
- Stanozolol-Induced Changes in Fibrinolysis and Coagulation in Healthy Adults (1984) (77)
- Alpha 2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity. (1987) (77)
- Cultured rat aortic vascular smooth muscle cells digest naturally produced extracellular matrix. Involvement of plasminogen-dependent and plasminogen-independent pathways. (1992) (72)
- Stabilization Versus Inhibition of TAFIa by Competitive Inhibitors in Vitro * (2003) (71)
- Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. (2000) (71)
- Factor VII polymorphisms in populations with different risks of cardiovascular disease. (1997) (70)
- Effect of 17β-Estradiol on Plasma Lipids and LDL Oxidation in Postmenopausal Women With Type II Diabetes Mellitus (1997) (70)
- HOMOZYGOUS α2-ANTIPLASMIN DEFICIENCY (1979) (69)
- Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. (1996) (69)
- Coagulation Factor VII, Dietary Fat and Blood Lipids: A Review (1996) (68)
- Familial elevation of plasma histidine‐rich glycoprotein in a family with thrombophilia (1987) (68)
- PAF-acether-induced release of tissue-type plasminogen activator from vessel walls. (1985) (68)
- Influence of Factor Xllla Activity on Human Whole Blood Clot Lysis In Vitro (1987) (67)
- Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. (1990) (65)
- Activation Products of the Haemostatic System in Coronary, Cerebrovascular and Peripheral Arterial Disease (2001) (64)
- Depression of Tissue Plasminogen Activator (t-PA) Activity and Rise of t-PA Inhibition and Acute Phase Reactants in Blood of Patients with Acute Myocardial Infarction (AMI) (1987) (64)
- Functional analogy between lipoprotein(a) and plasminogen in the binding to the kringle 4 binding protein, tetranectin. (1989) (63)
- Association of the tumour necrosis factor α −308G/A polymorphism with the risk of diabetes in an elderly population-based cohort (2002) (63)
- -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. (1998) (62)
- Effect of Strenuous Exercise on Fibrinogen and Fibrinolysis in Healthy Elderly Men and Women (1997) (61)
- Multicenter Evaluation of Commercially Available Methods for the Immunological Determination of Plasminogen Activator Inhibitor-1 (PAI-1) (1993) (60)
- Increased Euglobulin Fibrinolytic Potential in Women on Oral Contraceptives Low in Oestrogen – Levels of Extrinsic and Intrinsic Plasminogen Activators, Prekallikrein, Factor XII, and C1-Inactivator (1985) (60)
- Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. (2008) (60)
- Elevated Plasminogen Activator Inhibitor (PAI), a Cause of Thrombophilia? – A Study in 203 Patients with Familial or Sporadic Venous Thrombophilia (1989) (59)
- The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. (2003) (58)
- Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. (1988) (57)
- Demonstration of two forms of alpha 2-antiplasmin in plasma by modified crossed immunoelectrophoresis. (1981) (56)
- Mortality risk in men is associated with a common mutation in the methylenetetrahydrofolate reductase gene (MTHFR) (1999) (56)
- Determination of the habitual low blood level of C-reactive protein in individuals. (2001) (55)
- Gender-related association between beta-fibrinogen genotype and plasma fibrinogen levels and linkage disequilibrium at the fibrinogen locus in Greenland Inuit. (1995) (55)
- Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. (2007) (54)
- The Risk of Mortality and the Factor V Leiden Mutation in a Population-based Cohort (1998) (54)
- Logistics and quality control for DNA sampling in large multicenter studies (2003) (54)
- World distribution of factor V Leiden mutation (1996) (54)
- Modulation of Rapid Plasminogen Activator Inhibitor in Plasma by Stanozolol (1984) (53)
- Quantification of tissue-type plasminogen activator (t-PA) mRNA in human endothelial-cell cultures by hybridization with a t-PA cDNA probe. (1986) (53)
- Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina. (1996) (52)
- Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris (2003) (52)
- Effects of exercise training on plasminogen activator inhibitor activity. (1992) (51)
- Effects of Moderate Alcohol Consumption on Platelet Function, Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor (1990) (50)
- Histidine-rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis. (1989) (50)
- Sensitive markers of inflammation make it possible to study the chronic process: the rise of interest in low levels of C-reactive protein. (2002) (49)
- Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol. (2017) (48)
- A model for the harmonisation of test results of different quantitative D-dimer methods (2006) (48)
- Genetic Modulation of Coagulation Factor VII Plasma Levels: Contribution of Different Polymorphisms and Gender-related Effects (1998) (47)
- On the Role of C1-Inhibitor as Inhibitor of Tissue-type Plasminogen Activator in Human Plasma (1995) (47)
- Congenital plasminogen deficiency associated with venous thromboembolism: therapeutic trial with stanozolol (1986) (46)
- Association of APOE e2/e3/e4 and Promoter Gene Variants With Dementia But Not Cardiovascular Mortality in Old Age (2002) (46)
- Effects of Gemfibrozil and Ciprofibrate on Plasma Levels of Tissue-type Plasminogen Activator, Plasminogen Activator Inhibitor-1 and Fibrinogen in Hyperlipidaemic Patients (1997) (46)
- Update 1996: Blood collection and handling procedures for assessment of plasminogen activators and inhibitors (Leiden Fibrinolysis Workshop) (1996) (45)
- The association between inflammation markers, coronary artery disease and smoking. (2002) (44)
- Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects. (2014) (44)
- The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model (2018) (44)
- Decreased Levels of Histidine-Rich Glycoprotein (HRG) and Increased Levels of Free Plasminogen in Women on Oral Contraceptives Low in Estrogen (1982) (43)
- Acute exogenous hyperinsulinaemia does not result in elevation of plasma plasminogen activator inhibitor-1 (PAI-1) in humans (1990) (43)
- alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder. (1987) (43)
- Early spontaneous intermittent myocardial reperfusion during acute myocardial infarction is associated with augmented thrombogenic activity and less myocardial damage. (1995) (42)
- Exposure to secondhand smoke and depression and anxiety: a report from two studies in the Netherlands. (2013) (42)
- Tissue-type plasminogen activator (t-PA) : physiological and clinical aspects (1988) (42)
- Biological variation in inflammatory and hemostatic markers (2009) (41)
- Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model (2017) (41)
- Plasma homocysteine is weakly correlated with plasma endothelin and von Willebrand factor but not with endothelium-dependent vasodilatation in healthy postmenopausal women. (1999) (41)
- The mutual relationship between the two molecular forms of the major fibrinolysis inhibitor alpha-2-antiplasmin in blood. (1986) (41)
- Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables. (1990) (40)
- A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. (2006) (40)
- Acute effect of smoking on fibrinolysis: increase in the activity level of circulating extrinsic (tissue‐type) plasminogen activator* (1984) (40)
- Genetics of C-reactive protein: new possibilities and complications. (2003) (39)
- Inhibition of Tissue-Type Plasminogen Activator in Plasma of Women Using Oral Contraceptives and in Normal Women During a Menstrual Cycle (1986) (39)
- Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluated. (1994) (39)
- Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. (2006) (38)
- The Contribution of the Functional IL6R Polymorphism rs2228145, eQTLs and Other Genome-Wide SNPs to the Heritability of Plasma sIL-6R Levels (2014) (38)
- Quality assessment of CoaguChek point-of-care prothrombin time monitors: comparison of the European community-approved procedure and conventional external quality assessment. (2006) (38)
- Constitutive synthesis of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAT-1): Conditions and therapeutic targets (1994) (38)
- Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. (2008) (38)
- Physical Exercise Induces Enhancement of Urokinase-Type Plasminogen Activator (u-PA) Levels in Plasma (1991) (38)
- Apolipoprotein E phenotype and blood pressure (1994) (38)
- A national field study of quality assessment of CoaguChek point-of-care testing prothrombin time monitors. (2006) (37)
- Interrelationship between coagulant activity and tissue‐type plasminogen activator (t‐PA) system in acute ischaemic heart disease. Possible role of the endothelium (1990) (37)
- Fruit and vegetables and cardiovascular risk profile: a diet controlled intervention study (2001) (36)
- Importance of levonorgestrel dose in oral contraceptives for effects on coagulation (1999) (36)
- Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non‐anaesthetised volunteers (2018) (36)
- Multicentre Evaluation of Commercial Kit Methods: Plasminogen Activator Inhibitor Activity (1993) (36)
- Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia Study. (1998) (35)
- Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. (1996) (35)
- Discovery of biochemical biomarkers for aggression: A role for metabolomics in psychiatry (2016) (35)
- The Contact-System Dependent Plasminogen Activator from Human Plasma: Identification and Characterization (1990) (34)
- The long‐term within‐ and between‐laboratory variability for assay of antithrombin, and proteins C and S: results derived from the external quality assessment program for thrombophilia screening of the ECAT Foundation (2003) (34)
- Angiotensin I-converting enzyme and plasminogen activator inhibitor-1 gene variants: risk of mortality and fatal cardiovascular disease in an elderly population-based cohort. (1999) (34)
- The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol. (1986) (34)
- Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications. (2016) (34)
- Relationship of C-reactive protein with components of the metabolic syndrome in normal-weight and overweight elderly. (2005) (34)
- Factor VIIa response to a fat-rich meal does not depend on fatty acid composition: a randomized controlled trial. (1998) (34)
- Different Tissue Plasminogen Activator Release in the Arm and Leg during Venous Occlusion Is Equalized after DDAVP Infusion (1990) (33)
- Behaviour and Quantitation of Extrinsic (Tissue-Type) Plasminogen Activator in Human Blood (1983) (33)
- Genetic influences on fibrinogen, tissue plasminogen activatorantigen and von Willebrand factor in males and females (2006) (33)
- Fibrinogen Milano II: A Congenital Dysfibrinogenaemia Associated with Juvenile Arterial and Venous Thrombosis (1986) (33)
- Calcium-dependent binding of tetranectin to fibrin. (1989) (32)
- The Dutch Vascular Factors in Dementia Study: rationale and design (1997) (32)
- Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age. (2002) (32)
- Protein C, an anticoagulant protein, is increased in healthy volunteers and surgical patients after treatment with stanozolol. (1984) (32)
- Evidence for a QTL on chromosome 19 influencing LDL cholesterol levels in the general population (2003) (32)
- Alcohol and Fibrinolysis (1990) (31)
- The Fibrinolytic System and Thrombotic Tendency (2003) (31)
- Serum lipoprotein(a) level is related to thrombin generation and spontaneous intermittent coronary occlusion in patients with acute myocardial infarction. (1996) (31)
- Causes of variation in the neutrophil-lymphocyte and platelet-lymphocyte ratios: a twin-family study. (2016) (31)
- Liposomes: vehicles for the targeted and controlled delivery of peptides and proteins (1997) (30)
- Beneficial effect of a moderately energy-restricted diet on fibrinolytic factors in non-obese men. (1995) (30)
- Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study. (1991) (30)
- Blood sample stability at room temperature for counting red and white blood cells and platelets. (2002) (29)
- Treatment of Hereditary Protein C Deficiency with Stanozolol (1987) (29)
- Diurnal Variation in PAI-1 Activity Predominantly Confined to the 4G-allele of the PAI-1 Gene (2002) (29)
- Development of a procedure for coupling the homing device glu-plasminogen to liposomes. (1992) (28)
- Effect of propranolol (long-acting) on the circadian fluctuation of tissue-plasminogen activator and plasminogen activator inhibitor-1. (1991) (27)
- Association Between Postoperative Hyper-Response in t-PA Inhibition and Deep Vein Thrombosis (1986) (27)
- Alu-repeat polymorphism in the tissue-type plasminogen activator (t-PA) gene, t-PA levels and risk of familial myocardial infarction (MI) (1996) (27)
- Genome-wide analysis of DNA methylation in buccal cells: a study of monozygotic twins and mQTLs (2018) (27)
- Regular moderate wine consumption for five weeks increases plasma activity of the plasminogen activator inhibitor-1 (PAI-1) in healthy young volunteers (1990) (27)
- Contribution of factor VII, fibrinogen and fibrinolytic components to the risk of ischaemic cardiovascular disease: their genetic determinants (1998) (26)
- Bioimmunoassay for tissue-type plasminogen activator (t-PA) in human plasma: Evaluation of blood sampling and handling procedures and comparison with other t-PA activity methods (1992) (26)
- Mild Haemostatic Problems Associated with Congenital Heterozygous α2-Antiplasmin Deficiency (1988) (26)
- Modulation of Plasma Fibrinogen Levels by Ciprofibrate and Gemfibrozil in Primary Hyperlipidaemia (1994) (26)
- Biological variation in tPA-induced plasma clot lysis time (2012) (25)
- Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. (2002) (25)
- Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy. (2001) (25)
- Performance of semiquantitative and quantitative D-dimer assays in the ECAT external quality assessment program. (2000) (24)
- Genetic Architecture of the Pro-Inflammatory State in an Extended Twin-Family Design (2013) (23)
- Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus (2003) (23)
- New alleles in F7 VNTR. (1994) (23)
- FIBRIN DEGRADATION PRODUCTS ARE NOT SPECIFIC MARKERS FOR THROMBOLYSIS IN MYOCARDIAL INFARCTION (1987) (23)
- Genetic variation in Fcγ receptor IIa protects against advanced peripheral atherosclerosis (2004) (23)
- Long-term analytical performance of hemostasis field methods as assessed by evaluation of the results of an external quality assessment program for antithrombin. (2002) (22)
- The oral bioavailability of pentosan polysulphate sodium in healthy volunteers (1999) (22)
- Whole blood assay as a model for in vitro evaluation of inflammasome activation and subsequent caspase-mediated interleukin-1 beta release (2019) (22)
- Von Willebrand Factor, Plasminogen Activator Inhibitor-1 and C-Reactive Protein Are Markers of Thrombolytic Efficacy in Acute Myocardial Infarction (1992) (22)
- Coagulation and Fibrinolysis Markers and Risk of Dementia (1998) (22)
- Depression of factor XII-dependent fibrinolytic activity characterizes patients with early myocardial reinfarction after recombinant tissue-type plasminogen activator therapy. (1991) (21)
- Protein C Antigen Levels in Major Abdominal Surgery: Relationships to Deep Vein Thrombosis, Malignancy and Treatment with Stanozolol (1985) (21)
- No effect of folic acid supplementation in the course of 1 year on haemostasis markers and C-reactive protein in older adults (2005) (21)
- Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin. (1988) (21)
- Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. (1998) (21)
- Performance goals for the laboratory testing of antithrombin, protein C and protein S (2006) (20)
- Comparison of specificities of antigen assays for plasminogen activator inhibitor 1(PAI-1) (1990) (20)
- Evidence for a Role of Factor XII‐dependent Fibrinolysis in Cardiovascular Diseases (1992) (20)
- The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus. (2008) (20)
- SNP heritability and effects of genetic variants for neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio (2017) (20)
- Disorders of the hemostatic system and the risk of the development of thrombotic and cardiovascular diseases: limitations of laboratory diagnosis. (1990) (20)
- Response to Activated Protein C in Subjects with and without Dementia (1998) (20)
- The molecular form of alpha 2-antiplasmin with affinity for plasminogen is selectively bound to fibrin by factor XIII. (1984) (19)
- Longitudinal weight differences, gene expression, and blood biomarkers in BMI discordant identical twins (2015) (19)
- A powerful and rapid approach to human genome scanning using small quantities of genomic DNA. (2001) (19)
- Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women (2017) (19)
- Influence of 1-desamino-8-D-vasopressin on endogenous fibrinolysis, haemodynamics and liver blood flow in healthy subjects. (1994) (19)
- Effect of Moderate Alcohol Consumption on Fibrinogen Levels in Healthy Volunteers Is Discordant with Effects on C‐Reactive Protein (2001) (18)
- Disagreement between bedside and laboratory activated partial thromboplastin time and international normalized ratio for various novel anticoagulants (2001) (18)
- Effects on haemostasis variables by second and third generation combined oral contraceptives: a review of directly comparative studies. (2000) (18)
- Short term extreme increases in plasminogen activator inhibitor 1 (PAI-1) in plasma of polytrauma patients (1988) (18)
- Indicators of depressed fibrinolytic activity in pre‐operative prediction of deep venous thrombosis (1987) (18)
- Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin. (1990) (18)
- Fibrinolytic Activity in Peripheral Atherosclerosis in the Elderly (1999) (17)
- Thrombin generation after fast or prolonged regimens of tissue-type plasminogen activator (1993) (17)
- A Reference System Approach to Future Standardization of Laboratory Tests for Hemostasis, , (2002) (17)
- C-reactive protein: a cardiovascular risk factor report on the CRP hot-topic workshop October 1, 1997 (1998) (17)
- A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism. (1999) (17)
- Acid treatment of plasma for the inactivation of plasminogen activator inhibitor-1 (PAI-1). (1988) (17)
- The association of alcohol intake with γ-glutamyl transferase (GGT) levels: evidence for correlated genetic effects. (2014) (16)
- Renewed Interest in Haemostasis Changes Induced by Oral Contraceptives (OCs) (2000) (16)
- Protection of Single-chain Urokinase-type Plasminogen Activator (scu-PA) in Aprotinin Treated Cardiac Surgical Patients Undergoing Cardiopulmonary Bypass (1995) (16)
- Heritability and GWAS Studies for Monocyte–Lymphocyte Ratio (2017) (16)
- Postprandial response of activated factor VII in elderly women depends on the R353Q polymorphism. (1999) (16)
- Depression of factor XII-dependent fibrinolytic activity in survivors of acute myocardial infarction at risk of reinfarction. (1993) (15)
- Thrombotic Complications During L-Asparaginase Related to Protein C Deficiency? (1985) (15)
- Applying caspase-1 inhibitors for inflammasome assays in human whole blood. (2014) (15)
- The effect of 17β-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus (2002) (15)
- DNA methylation signatures of aggression and closely related constructs: A meta-analysis of epigenome-wide studies across the lifespan (2020) (15)
- Combined association and linkage analysis applied to the APOE locus (2004) (15)
- Changes in coagulation and fibrinolysis variables during use of two oral contraceptives containing the same dose of ethinyl estradiol and either gestodene or desogestrel. (1990) (14)
- Quantitation of Plasma Levels of Tetranectin - Effects of Oral Contraceptives, Pregnancy, Treatment with L-Asparaginase and Liver Cirrhosis (1989) (14)
- Clearance of Plasminogen Activators—A Major Determinant of Plasma Concentration: Therapeutic and Diagnostic Implications (1992) (14)
- Identifying patients at risk of coronary vascular disease: the potential role of inflammatory markers (2004) (14)
- Effect of Isotretinoin on Endogenous Tissue-Type Plasminogen Activator (t-PA) and Plasminogen Activator Inhibitor 1 (PAI-1) in Humans (1993) (14)
- External quality assessment for thrombin generation tests: an exploration. (2010) (14)
- Improved Assay Conditions for Automated Antithrombin III Determinations with the Chromogenic Substrate S-2238 (1984) (14)
- The association between extrinsic activated protein C resistance and venous thromboembolism in women. (2002) (14)
- Pharmacokinetics of Saruplase, a Recombinant Unglycosylated Human Single-Chain Urokinase-Type Plasminogen Activator and Its Effects on Fibrinolytic and Haemostatic Parameters in Healthy Male Subjects (1993) (14)
- Assessing Safety of Thrombolytic Therapy (2016) (13)
- PLASMA HISTIDINE-RICH GLYCOPROTEIN AND THROMBOPHILIA (1988) (13)
- Haemostasis Contact System and Fibrinolysis in Hereditary Angioedema (Cl-Inhibitor Deficiency) (1988) (13)
- Coagulation Factor VII, Serum-Triglycerides and the R/Q353 Polymorphism: Differences between Older Men and Women (1997) (13)
- Effect of Genome and Environment on Metabolic and Inflammatory Profiles (2015) (13)
- The harmonization of quantitative test results of different D-dimer methods. (2005) (13)
- Evaluation of the specificity of antigen assays for plasminogen activator inhibitor 1: Comparison of two new commercial kits (1992) (13)
- The pharmacokinetics of recombinant double‐chain t‐PA (duteplase): Effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction (1991) (13)
- Genetics of dizygotic twinning: a feasibility study for a biobank. (2004) (13)
- Chronobiology of coronary risk markers in Greenland Eskimos: a comparative study with Caucasians residing in the same Arctic area. (1991) (13)
- Urinary Amine and Organic Acid Metabolites Evaluated as Markers for Childhood Aggression: The ACTION Biomarker Study (2020) (13)
- Platelet‐derived Growth Factor Increases Plasminogen Activator Inhibitor‐1 Activity and mRNA in Rat Cultured Vascular Smooth Muscle (1992) (13)
- Dietary effects on coagulation factor VII vary across genotypes of the R/Q353 polymorphism in elderly people. (1998) (13)
- Modified Crossed Immunoelectrophoresis to Study with Whole Plasma the Reversible Complex Formation of Histidine-Rich Glycoprotein with Plasminogen (1988) (13)
- Insulin resistance and changes in haemostatic variables (1992) (12)
- Diminished release of tissue plasminogen activator during venous occlusion in manual workers (1988) (12)
- Plasma factor VII-activating protease is increased by oral contraceptives and induces factor VII activation in-vivo. (2011) (12)
- Angiotensin-converting enzyme inhibitor trandolapril does not affect C-reactive protein levels in myocardial infarction patients. (2003) (12)
- Procoagulant activity and intimal dysfunction in IDDM (2006) (12)
- The association between birth weight and plasma fibrinogen is abolished after the elimination of genetic influences (2003) (12)
- Individual levels of plasma histidine-rich glycoprotein (HRG) during the normal menstrual cycle and in women on oral contraceptives low in oestrogen. (1982) (12)
- Effects of liver blood flow on the pharmacokinetics of tissue‐type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction (1998) (11)
- The Suitability of Various Plasmin Preparations for the Functional Assay of α2-Antiplasmin in Plasma (1982) (11)
- Metabolic profile of a continuous versus a cyclic low-dose combined oral contraceptive after one year of use (2011) (11)
- A thrombin generation assay may reduce the need for compression ultrasonography for the exclusion of deep venous thrombosis in the elderly (2011) (11)
- Detecting molecular forms of antithrombin by LC-MRM-MS: defining the measurands (2018) (11)
- Direct assay of factor XIIa in plasma with synthetic chromogenic substrates. (1983) (10)
- Effects of four days of moderate wine and coffee consumption on fibrinolysis and platelet aggregation (1990) (10)
- Pathomechanisms of Defective Hemostasis During and After Extracorporeal Circulation: Contact Phase Activation (1991) (10)
- DNA-Polymorphisms and Plasma Levels of Vascular Disease Risk Factors in Greenland Inuit (1999) (10)
- Two-locus Linkage Analysis Applied to Putative Quantitative Trait Loci for Lipoprotein(a) Levels (2003) (10)
- Effect of 17 beta-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus. (1997) (10)
- Effects of hormone treatment on hemostasis variables (2007) (10)
- Hormone replacement therapy: a useful tool in the prevention of coronary artery disease in postmenopausal women? (1996) (10)
- Effects of Oral Stanozolol Used in the Prevention of Postoperative Deep Vein Thrombosis on Fibrinolytic Activity (1985) (10)
- Influence of Heparin and a Low Molecular Weight Heparinoid on Specific Endogenous and Exogenous Fibrinolytic Factors during Rest and Exercise (1992) (10)
- Circadian variations of extrinsic fibrinolytic components in blood from eskimos (1990) (9)
- Life style and blood fibrinolytic activity: a comment on clearance of plasminogen activators (1990) (9)
- In Vitro Diagnosis of Fibrinolysis: Present Status and Desired Improvements (1992) (9)
- THE MUTUAL RELATION BETWEEN THE 2 MOLECULAR-FORMS OF ALPHA-2-ANTIPLASMIN IN BLOOD (1983) (9)
- 13 Circadian variation of fibrinolytic factors in young healthy subjects (1988) (9)
- Non-Esterified Fatty Acids are Related with Hypofibrinolysis in Type 2 Diabetes Mellitus (1994) (9)
- Genetic polymorphisms modify the response of factor VII to oral contraceptive use: an example of gene-environment interaction. (2002) (9)
- Triazolobenzodiazepines: a new class of stimulators of tissue-type plasminogen activator synthesis in human endothelial cells. (1993) (9)
- The effect of 17 beta-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus. (2002) (9)
- Assignment of the human tissue-type plasminogen activator gene (PLAT) to chromosome 8 (1986) (9)
- Diabetes as a procoagulant condition (2002) (8)
- Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential (2005) (8)
- Clot Accumulation Characteristics of Plasminogen-bearing Liposomes in a Flow-system (1998) (8)
- No Effect of Unfractioned or Low Molecular Weight Heparin Treatment on Markers of Vascular Wall and Hemostatic Function in Incipient Diabetic Nephropathy (1997) (8)
- Fibrinolytic capacity and risk of myocardial infarction (1996) (8)
- Plasminogen Activation in Fibrinolysis, in Tissue Remodeling, and in Development. Proceedings of a conference. Leiden, the Netherlands, October 22-25, 1991. (1992) (8)
- Sex hormone‐binding globulin as a marker for the thrombotic risk of hormonal contraceptives: a rebuttal (2013) (8)
- Factors affecting the relation between plasminogen activator inhibitor (PAI) activity and PAI-1 antigen levels in normals and in patients with arterial disease (1990) (8)
- Appropriate milieu for the assay of alpha-2-antiplasmin activity with chromogenic substrates. (1985) (8)
- Antibodies to Chlamydia pneumoniae and clinical course in patients with unstable angina pectoris. (2000) (8)
- Circadian patterns of plasma t-PA and PAI-1 antigen levels in patients with severe peripheral atherosclerosis (1996) (8)
- Estrogen receptor 1 haplotype does not regulate oral contraceptive-induced changes in haemostasis and inflammation risk factors for venous and arterial thrombosis. (2006) (7)
- Evolution of Urokinase-Type Plasminogen Activator (u-PA) and Tissue-Type Plasminogen Activator (t-PA) in Orthotopic Liver Transplantation (OLT) (1993) (7)
- The potency of the fibrinolytic system detected by a new assay for α2-antiplasmin - plasmin complex determination in human plasma (1992) (7)
- Principles of use of surrogate markers and endpoints. (2004) (7)
- Introduction to haemostasis from a pharmacodynamic perspective. (2011) (7)
- Vitreous and subretinal fluid concentrations of orally administered dabigatran in patients with rhegmatogenous retinal detachment (2016) (6)
- Endothelial Binding of Recombinant Tissue Plasminogen Activator: Quantification In Vivo Using a Recirculatory Model (2003) (6)
- Long-term stability of liposomes containing both tissue-type plasminogen activator and glu-plasminogen (1996) (6)
- Moderate alcohol consumption and fibrinolytic factors of pre- and postmenopausal women (2001) (6)
- Evaluation of a bioimmuno assay for t-PA activity and its relation to PAI-1 activity and antigen levels (1998) (6)
- Evaluation of euglobulin methods for the study of blood fibrinolytic activity: results for patients with rheumatoid arthritis and in the postoperative period. (1985) (6)
- On the route to combined evidence from OC and HRT/ERT. (2002) (6)
- A Dose-Escalating Study With the Fetal Estrogen Estetrol in Healthy Men (2018) (6)
- Review: Diabetes as a procoagulant condition (2002) (6)
- Effect of Genomics on Venous Thrombosis: Relation to Sex Steroids (2006) (6)
- The 4G/5G-polymorphism in the PAI-1 gene is not associated with markers of atherosclerosis in male smokers. (2002) (6)
- Polymorphism of the blood clot lysis enzyme tissue-type plasminogen activator is associated with myocardial infarction (1995) (6)
- Fibrinolysis in insulin-dependent diabetic patients with and without nephropathy (1996) (6)
- Association between systemic generation of plasmin and activation of the factor XII-dependent fibrinolytic proactivator system in coronary thrombolysis (1992) (6)
- Revised Reference Curve for the α2-Antiplasmin Assay by the Addition of Detergents (1984) (6)
- Activators and inhibitors of fibrinolysis in rheumatoid joint inflammation (1977) (6)
- Preincubation in the Prothrombinase‐induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban (2013) (6)
- Baseline levels of α2-antiplasmin-plasmin complex in human plasma (1994) (5)
- Hereditary Cerebral Hemorrhage with Amyloidosis -Dutch Type: A Study of Fibrinolysis (1992) (5)
- Criteria for a specific plasmin inhibition test (SPIT) in human plasma (1996) (5)
- Strongly increased levels of fibrinogen elastase degradation products in patients with ischemic stroke (2008) (5)
- Plasma levels of TAFI are elevated in patients with unstable angina pectoris (UAP) compared to stable angina pectoris, but show no relationship with outcome of severe UAP (2001) (5)
- Adult aggressive behavior in humans and biomarkers: a focus on lipids and methylation (2018) (5)
- Interaction study between nifedipine and recombinant tissue-type plasminogen activator in healthy subjects. (1993) (5)
- Smoking and CRP: results of the Arnhem Elderly Study (2001) (5)
- Increased Urokinase-Type Plasminogen Activator (u-PA) Levels in Graft Liver Perfusate and Decreased Single Chain u-PA Activation with Higher Levels of Aprotinin (1994) (5)
- An Enhancing Effect Of Smoking On Fibrinolysis (1981) (5)
- Activation of coagulation and fibrinolysis in acute or chronic coronary artery disease (1994) (5)
- Scientific and Standardization Committee Communication: A Reference System Approach to Future Standardization of (2001) (5)
- Inflammatory markers as predictors in unstable angina (1997) (4)
- A novel method, COAMATIC® plasmin inhibitor, for the specific determination of Plasmin Inhibitor activity in plasma (1996) (4)
- Platelet plasminogen activator inhibitor type 1 (PAI-1) in insulin-dependent diabetes mellitus (1992) (4)
- HRT effects on inflammatory markers: is chronic inflammation a contra-indication for HRT? (2002) (4)
- In low-dose oral contraceptives containing 20 μg or 30 μg ethinylestradiol, gestodene is associated with a lower increase in coagulant factor VII than is desogestrel (1996) (4)
- Comparison of the effects of a contraceptive patch and oral contraceptives on coagulation parameters (2000) (4)
- High-dose aspirin, thrombin, and coronary angioplasty (1993) (4)
- New aspects of blood collection and handling procedures for the assessment of t-PA and PAI-1 variables after the introduction of acid blood collection (1994) (4)
- Discriminant analysis of the metabolic effects of a new combined contraceptive vaginal ring containing Nestorone/EE vs. a second-generation oral contraceptive containing levonorgestrel/EE. (2012) (4)
- ABNORMAL FIBRINOLYSIS IN PROGRESSIVE RENAL-FAILURE DUE TO A REDUCTION IN CIRCULATING TISSUE PLASMINOGEN-ACTIVATOR (1988) (4)
- Plasminogen Activator Inhibitor-1 (PAI-1) Antigen, PAI Activity and Tissue-Type Plasminogen Activator (t-PA) Antigen have, in Bedridden Volunteers, a Diurnal Rhythm with Approximately the Same Phase and a Peak Late in the Morning (1992) (4)
- Changes in urokinase-type plasminogen activator in orthotopic liver transplantation. (1993) (4)
- Effects of Coffee and Caffeine on Tissue-Type Plasminogen Activator and its Fast-Acting Inhibitor, PAI-1, In Vivo and In Vitro (1990) (4)
- A Common Calibrator Does Not Secure Harmonisation of Commercial t-PA and PAI-1 Antigen Measurements (2001) (4)
- The effect of chemical anti-inhibitors on fibrinolytic enzymes and inhibitors. (1997) (4)
- Relationship between CRP and clinical course of unstable angina depends on assay method. (2002) (4)
- INAPPROPRIATE INHIBITION AT THE PLASMIN LEVEL MAY CONTRIBUTE TO ENHANCED FIBRINOLYSIS IN ADVANCED LIVER CIRRHOSIS (1988) (4)
- PROPOSAL FOR A GENERAL STRATEGY OF STANDARDIZATION OF FIBRINOLYSIS ASSAYS TO BE USED IN CLINICAL PRACTICE (1999) (4)
- Fibrinolytic agents and their effects on the haemostatic system. (1988) (4)
- Oral contraceptives and hemostasis (1996) (4)
- Quality assessment of coaguchek monitors: comparative analysis of the ECAA and conventional external QA (2007) (4)
- Increased impact of a contraceptive vaginal ring with ethinyl estradiol and nestorone on C-reactive protein (2012) (4)
- α1-ANTIPLASMIN AND THROMBOSIS: RESULTS OF A QUESTIONNAIRE (1988) (4)
- EditorialPro-inflammatory effect of oestrogens (1999) (4)
- The effect of the relationship between tissue-type plasminogen activator and plasminogen activator inhibitor type 1 on tissue-type plasminogen activator activity in insulin-dependent diabetes mellitus (1994) (4)
- Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function (1999) (4)
- Fibrin Binding of Plasminogen Coated Liposomes In Vitro (1996) (4)
- DEFICIENCY OF ALPHA-2-PLASMIN INHIBITOR AND HEMORRHAGIC DIATHESIS (1980) (3)
- A Rebuttal - Oral Contraceptives and Venous Thrombosis: Reply (2001) (3)
- Genetic studies of complex diseases: Giant steps from promise to proof (1996) (3)
- How best to counteract the enemies? By controlling inflammation in the coronary circulation (2002) (3)
- Genetic research stimulates development of individual treatment. (1999) (3)
- Blood sampling techniques for fibrinolytic studies: comparison of Vacutainer R and traditional techniques. (1981) (3)
- Consumption of reduced-fat products, haemostatic parameters and oral glucose tolerance test (1996) (3)
- Various approaches to standardization and the importance of measurement accuracy (1996) (3)
- Dose dependent effects of atorvastatin on C-reactive protein in type 2 diabetes mellitus (2001) (3)
- Acute effects of moderate alcohol consumption on fibrinolytic factors in healthy middle-aged men (1993) (3)
- Clearance of plasminogen activator--a major determinant of plasma concentration: therapeutic and diagnostic implications. (1992) (3)
- Protection against venous thrombosis in an antithrombin-III deficient patient suffering from episodes of arterial thrombosis requiring major surgery. Effects of oral stanozolol in combination with subcutaneous heparin and intravenous AT-III. (1985) (3)
- Genetics of dizygotic twinning. Design and sample collection: A feasibility study. (2004) (3)
- Diagnostic possibilities of specific fibrin(ogen) degradation products in relation to venous thromboembolism (2013) (3)
- Consequences for the APTT due to direct action of factor XIa on factor X, resulting in bypassing factors VIII-IX. (2015) (3)
- Recovery and stability of Plasminogen Activator Inhibitor (PAI) activity in human platelet extracts (1992) (3)
- New Prospects in the Activation of Fibrinolysis (1980) (3)
- EFFECT OF DDAVP ON PLASMA LEVELS OF FACTOR VII AND XII (1984) (3)
- Effect of fish oil and vitamin E on the cardiovascular risk indicators fibrinogen, C-reactive protein and PAI activity in healthy young volunteers (1994) (3)
- A monoclonal antibody against the COOH-terminal site of α2-antiplasmin reveals heterogeneity in the non-plasminogen binding form of α2-antiplasmin (1996) (3)
- The use of Stabilyte® plasma may cause changes in pH in the assay of some fibrinolysis analytes and might effect results* (1996) (3)
- Inhibition of fibrinolysis in blood: circadian fluctuation and possible relevance to coronary artery disease (1989) (3)
- 7. Modulation of plasma fibrinogen levels by medication (1996) (2)
- Deviations in factor XII-dependent plasminogen activator activity in relation to ischaemic heart disease and age (1992) (2)
- Interactions of sugammadex with various anticoagulants . (2020) (2)
- 167. Reduced response to activated protein C is associated with risk of stroke and transient ischaemic attack (1996) (2)
- The Estimation Of α2-Antiplasmin By Means Of Synthetic Substrates; Kinetic Analysis And Optimization Of The Method (1981) (2)
- Criteria and Search for Specific Assays for Active Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma (2000) (2)
- A RANDOMISED DOSE RANGING STUDY OF TWO-CHAIN TISSUE-TYPE PLASMINOGEN ACTIVATOR (BW-t-PA) IN MYOCARDIAL INFARCTION: IN VITRO MONITORING (1987) (2)
- 40. Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris (1996) (2)
- Activated protein C response and cardiovascular risk factors in the elderly. The Rotterdam Study (1996) (2)
- C-reactive protein: Associations with cardiovascular risk factors and all-cause mortality in elderly (2000) (2)
- Genetics of Dizygotic Twinning: A Feasibility Study for a Biobank (2004) (2)
- Effect of age, time of day and arterial disease on the relation between tissue-type plasminogen activator and plasminogen activator inhibitor-1 in plasma (1992) (2)
- Local tissue factor pathway inhibitor release in the human forearm (2003) (2)
- How to search for the role of gene-environment interactions for lipids in humans. (2002) (2)
- Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: results of the ECAPTURE study* (2001) (2)
- Plasma Cotinine Levels in Cigarette Smokers: Impact of Mental Health and Other Correlates (2014) (2)
- QUANTIFICATION OF THE MEASUREMENT UNCERTAINTY FOR D-DIMER ASSAY RESULTS AROUND THE CUT-OFF LEVEL: IMPROVED DECISION RULES REQUIRED? (2007) (2)
- PGM Guidelines for Description of Criteria and Methods for Testing of Specificity of Assay Methods for Quantities in the Fibrinolytic System (2000) (2)
- Tissue-type plasminogen activator (t-PA) activity (1999) (2)
- Thrombin Generation in Vitreous and Subretinal Fluid of Patients with Retinal Detachment (2018) (2)
- Integrative Multi-omics Analysis of Childhood Aggressive Behavior (2021) (2)
- Interference of ϵ-amino-caproic acid with [N-succinimidyl S-acetylthioacetate derived] thiol-introduction into glu-plasminogen (1994) (2)
- Different effects of lipopolysaccharide on plasminogen activator inhibitor-1 production in aortic media in vivo and in culture (2004) (2)
- Analysis of activation markers of coagulation, fibrinolysis and inflammation in unstable angina by probit transformation* (1996) (2)
- Usefulness and limitations of Actilyse® for standardisation of tissue-type plasminogen activator (t-PA) assays in blood (1996) (2)
- Frequent sampling by clear venipuncture in unstable angina is a reliable method to assess haemostatic system activity (1994) (2)
- Increased risk of mortality associated with a common mutation in the methylenetetrahydrofolate reductase gene (MTHFR) (1999) (2)
- MECHANISM OF PLASMINOGEN ACTIVATION AT LOW TEMPERATURE IN PLASMA SAMPLES CONTAINING THERAPEUTIC CONCENTRATIONS OF t-PA (1987) (2)
- 391 Histidine-rich glycoprotein (HRG) is normal in child A and decreased in child C liver cirrhosis (1988) (2)
- The Rationale of Prevention of Thrombosis by Enhancing Blood Levels of Single‐Chain Urokinase‐type Plasminogen Activator (scuPA) (1992) (2)
- Higher vitreous concentrations of dabigatran after repeated oral administration (2017) (2)
- ORIGINAL COMMUNICATION Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study (2002) (2)
- Low-dose infusion of recombinant tissue-type plasminogen activator in healthy volunteers to investigate the biodistribution of t-PA in the early phase of infusion (1997) (2)
- Heritability of Urinary Amines, Organic Acids, and Steroid Hormones in Children (2022) (2)
- GENETICS OF MYOCARDIAL INFARCTION : HAEMOCOAGULATIVE ASPECTS (1997) (2)
- Diurnal variation of PAI-1 partly explained by 4G5G polymorphism (2000) (2)
- Patients with deep venous thrombosis and thrombophilia risk factors have a specific prolongation of the lag time in a chromogenic thrombin generation assay (2011) (2)
- A national field study of quality assessment (qa) og coaguchek monitors (2007) (1)
- The Acute-Phase Reaction of the Fibrinolytic System in Acute Myocardial Infarction and Unstable Angina (2019) (1)
- Prolonged Coagulation Instability is Associated with a Higher‐dose Regimen of Tissue‐type Plasminogen Activator in Patients with Acute Myocardial Infraction (1992) (1)
- Factor XII dependent fibrinolytic activity is decreased in the acute phase of myocardial or cerebral infarction (1996) (1)
- Enhancement of in vitro plasma fibrinolysis by sulphated polysaccharides (1980) (1)
- FIBRIN DEGRADATION PRODUCTS (FbDP) IN HEALTHY VOLUNTEERS AFTER INFUSION OF RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR(rt-PA) (1987) (1)
- Genome-wide analysis of DNA methylation in buccal cells: a study of monozygotic twins and mQTLs (2018) (1)
- THE INFLUENCE OF CROSSLINKING BY FACTOR-XIII ON LYSIS OF WHOLE AND DILUTED BLOOD-CLOTS - AVOIDANCE OF INTERFERENCE BY ANTI-COAGULANT AND ROLE OF ALPHA-2-ANTIPLASMIN (1983) (1)
- Contact activation patterns of human plasma measured with a fluorogenic substrate. (1983) (1)
- Marked reduction of procoagulant acute phase proteins early coronary thrombolysis (1990) (1)
- Reduced response to activated protein C is associated with risk of stroke and transient ischaemic attack (abstract) (1996) (1)
- t-PA and family history of thrombosis in AMI patients from gissi trial : Biochemical and genetic aspects (1994) (1)
- Circadian variation of fibrinolytic activity among Eskimos in Greenland. (1989) (1)
- Prothrombin fragment 1+2, a marker of thrombin formation, is related to transcapillary escape rate of albumin in insulin-dependent diabetic patients (1993) (1)
- Genome scan for quantitative traits involved in cardiovasculair disease in three independent populations (2001) (1)
- APC-PCI complex as new tool for the evaluation of anticoagulant response to endogenous thrombin formation and its sequel in fibrinolysis (2010) (1)
- [Clinical presentation of unstable angina may influence the formation of thrombin during spontaneous episodes of ischemia]. (1998) (1)
- High-dose aspirin, thrombin, and coronary angioplasty (letter to the editor) (1993) (1)
- Concentration changes during venous occlusion of proteins with affinity for extracellular matrix in insulin-dependent diabetes mellitus A sign of vascular damage in patients with diabetic nephropathy? (1999) (1)
- 130 Stromelysin promoter polymorphism is associated with the progression of coronary heart disease (1997) (1)
- Fibrinogen Milan II: A congenital dysfibrinogenemia with a defective clotting by thrombin, normal clotting by arvin, reptilase and prothrombin-staphy1ocoagulase complex, associated with thrombotic episodes (1985) (1)
- Dose-dependent lowering of hs-CRP with statin therapy (2001) (1)
- Hormone replacement therapy: a useful tool in the prevention of coronary artery disease in postmenopausal women? Working Group on Women and Cardiovascular Disease of The Netherlands Heart Foundation. (1996) (1)
- Fibrinolysis and extracorporeal circulation. (1992) (1)
- Plasma plasminogen activator levels increase progressively during prolonged exercise (1990) (1)
- The effect of monophasic oral contraceptive regimens on Factor VII-activating Protease - a randomized multicentre study (2009) (1)
- Fibrinogens “Milano II” - and “Naples” (1987) (1)
- Variable depletion of endogenous factor XII-dependent fibrinolytic activity following thrombolytic therapy of myocardial infarction and its relation to reinfarction. (1992) (1)
- Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: results of the ECAPTURE study. European Concerted Action on Prevention from Thrombosis by URokinase Enhancement. (2001) (1)
- Response to Activated Protein C and Cerebrovascular Disease (1997) (1)
- Effect of short-term postmenopausal estrogen replacement therapy in women with non-insulin-dependent diabetes mellitus on endothelial function parameters in blood (1996) (1)
- Is acute coronary recanalization thrombogenic in man (1992) (1)
- The effect of gliclazide on plasma urokinase-related fibrinolysis. The results from an exploratory study (1994) (1)
- Congenital deficiencies in α2-antiplasmin (1984) (1)
- Thrombin-antithrombin iii complexes during thrombolytic therapy with rt-PA in acute myocardial infarction (1992) (1)
- FIBRINOLYTIC ACTIVITY IN PROTEIN S DEFICIENCY (1988) (1)
- Populationpharmacokinetic/pharmacodynamic modeling of a new recombinant human factor VIIA (LR769) to derive the dose to be studied in phase 3 (2015) (1)
- 190 Dose linearity and differentiation of in vitro and in vivo effects of RT-PA on haemostatic parameters in healthy men (1988) (1)
- Influence of some organic and inorganic ions on fibrinolysis in vitro. (1976) (1)
- ID: 134 Fibrin degradation by various enzymes: consequences for D-dimer tests. (2006) (1)
- Population Pharmacokinetic/Pharmacodynamic Modeling of a Next Generation Recombinant Human Factor VIIa (LR769) to Derive the Dose to be Studied in Phase 3 (2015) (0)
- Preface Twenty‐five Years of the Gaubius Institute (1992) (0)
- oscillation of plasma PAI-1 The 4G5G polymorphism in the gene for PAI-1 and the circadian (2013) (0)
- Plasminogen activator inhibitor-1: A novel biochemical of coronary reperfusion (1990) (0)
- Editorial. Proceedings of the 3rd European Consensus Development Conference on Sex Steroids and Cardiovascular Diseases. November (2004) (0)
- Can we reduce thrombin generation during coronary thrombolysis or coronary angioplasty (1995) (0)
- Study design for the identification of loci affecting human longevity (1996) (0)
- Twenty-five years of the Gaubius Institute. (1992) (0)
- Rapid and stable accumulation on thrombi of liposomes with attached plasminogen (1996) (0)
- Coagulation factor VII and serum-triglycerides in elderly people: gene-environment interaction. (1996) (0)
- Logistics and quality control for DNA sampling in large population-based studies (2001) (0)
- Acute lymphocytic leukaemia complicated by hypofibrinogenaemia without evidence for impaired fibrinogen synthesis or disseminated intravascular coagulation. (1983) (0)
- [Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human]. (1988) (0)
- Enhancement of protein C by stanozolol in healthy adults and in surgical patients : abstract (1983) (0)
- Effect of percentage and type of dietary fat on rat plasma tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI) (1990) (0)
- Some Characteristics of Commercially Available Human Glu-Plasminogen Preparations (1994) (0)
- 15 The state of the fibrinolytic system during the early phase of myocardial infarction and unstable angina (1988) (0)
- THE THROMBIN GENERATION TEST NEEDS TO BE SUPPLEMENTED WITH ADDITIONAL TESTS TO FULLY DOCUMENT THE EFFECTS OF THROMBIN INHIBITORS: EVALUATION FOR MELAGATRAN (2007) (0)
- PROGNOSTIC SIGNIFICANCE OF HAEMOSTATIC VARIABLES IN ACUTE STROKE (1987) (0)
- ID: 135 Products of limited elastase/cathepsin G degradation of fibrinogen as new biomarker in cardiovascular disease. (2006) (0)
- Tissue type plasminogen activator, atherosclerosis and the risk of myocardial infarction (1996) (0)
- Estrogen receptor-1 genotypes do not influence baseline levels of hemostasis and lipid risk markers for cardiovascular disease in young women (2006) (0)
- In vitro binding of free and liposomal gluplasminogen to fibrin (1994) (0)
- Leiden fibrinolysis & proteolysis workshop 7, extracellular proteolysis and epidemiology, proceedings of a Workshop, Leiden, The Netherlands, 22-24 April, 1998 (1999) (0)
- Is fibrinolysis critical for acute coronary syndromes? (2001) (0)
- Effect of a 6 months training programme on fibrinogen and PAI1-ag in elderly people (abstract) (1996) (0)
- Thrombin-activatable fibrinolysis inhibitor antigen levels and the prevalence of the -438a/g promoter polymorphism in patients with unstable angina pectoris (2001) (0)
- fibrinolysis inhibitor alpha-2-antiplasmin in blood The mutual relationship between the two molecular forms of the major (2011) (0)
- Effect of CRP method on association with clinical course in patients with unstable angina pectoris (2001) (0)
- Urokinase-type plasminogen activator (u-PA) and the risk of coronary events in patients with angina pectoris (AP) (1998) (0)
- STUDIES ON THE CONSUMPTION OF THE PLASMINOGEN-BINDING (PB) AND NON-PB FORMS OF α2-ANTIPLASMIN BY ACTIVATING PLASMINOGEN IN PLASMA WITH t-PA IN VITRO AND IN VIVO (1987) (0)
- [Congenital deficiency of the fibrinolysis inhibitor alpha 2-antiplasmin as a cause of hemorrhagic diathesis]. (1988) (0)
- Plasminmedieret aktivering af koagulationssystemet. [Plasmin mediated activation of coagulation in patients receiving recombinant tissue plasminogen activator] (1994) (0)
- The Concentration of Exogenously Added Lipids and Endogenously Available Microparticles Are Major Determinants of Thrombin Generation in Plasma. (2006) (0)
- 22-Antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin (2005) (0)
- The influence of crooslinking by factor XIII on lysis of whole and diluted blood clots : avoidance of interference by anticoagulants and role of α_2-antiplasmin. Abstract (1983) (0)
- 17 β-oestradiol improves carbohydrate metabolism in postmenopausal women with type 2 diabetes mellitus (1995) (0)
- Do Elevated Plasma Tissue Factor Pathway Inhibitor (TFPI) Levels Affect Measurement of Factor VIIa (2004) (0)
- t-PA and PAI-1 release after different stimuli in deep vein thrombosis (1990) (0)
- Assay And Occurrence Of Two Molecular Forms Of α2-Anti- Plasmin In Plasma (1981) (0)
- A lack of coupling between the expression of the UK and the t-PA/PAI-1 systems in patients with acute ischaemic hart disease (1990) (0)
- Congenital deficiencis of fibrinolysis (1990) (0)
- Is thrombolytic therapy most effective when endogenous fibrinolysis is deficient (1996) (0)
- The Effects of D-DAVP on T-PA Concentrations in Man: The Influence of Liver Blood Flow (1992) (0)
- RESULTS OF A DUTCH QUESTIONNAIRE ON HAEMOSTASIS IN GASTRO-ENTEROLOGY AND LIVER DISEASE. Part II: Gastro-enterology (1988) (0)
- Measurement of contact-activation patterns of human plasma samples with synthetic substrates. (1988) (0)
- Recombinant Plasmin from Lemna: Purification, Characterization and In Vitro Comparison with Human Plasma-Derived Plasmin. (2006) (0)
- 2.P.368 Factor VII: A responds to fatty meals, independently of fat composition (1997) (0)
- Abstract 342: Coagulation Pathways Drive Substantial Leukocyte Recruitment Relative to Solitary TLR4-mediated Pathways (2013) (0)
- Genetic polymorphisms: applications in family and population studies (1993) (0)
- No effect of folic acid supplementation on hemostasis markers in healthy elderly (2003) (0)
- Altered cytokine profiles in patients with chronic fatigue syndrome and differential sensitivity to glucocorticoids (1997) (0)
- 152. Inflammatory markers as predictors in unstable angina (1996) (0)
- A recirculatory model for tissue plasminogen activator with saturable endothelial binding (2002) (0)
- Angiotensin increases plasminogen activator inhibitor activity and MRNA in cultured rat vascular smooth muscle cells (1994) (0)
- Thyroid hormones T 3 and T 4 and their relationship with fibrinolysis variables (2010) (0)
- Genome scan for quantitative traits involved in cardiovascular disease (1999) (0)
- α_2-antiplasmin, the major inhibitor of fibrinolysis : abstract (1983) (0)
- ID: 118 The repeatability of quantitative D-Dimer assays in clinical laboratories. (2006) (0)
- Coagulation factor VII dietary fat and fibre in elderly people. The Second European Congress on Nutrition and Health in the Elderly, 1996, Elsinore, Denmark. (1997) (0)
- CONTACT ACTIVATION AND SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR (1987) (0)
- The interrelation between coagulant activity and the t-PA system in ischaemic heart disease. Possible involvement of the endothelium (1990) (0)
- TAFI antigen and plasminogen concentrations in plasma: study in plasminogen deficiency (2001) (0)
- a 2-Antiplasmin Enschede : Dysfunctional a 2-Antiplasmin Molecule Associated with an Autosomal Recessive Hemorrhagic Disorder (2013) (0)
- Effect of isotretinoin on endogenous t-PA and PAI-1. (1993) (0)
- Serum-triglycerides and coagulation factor VII in elderly people; evidence for gene-environment interaction. (1996) (0)
- Inflammation in type II diabetics is not a major determinant of cardiovascular risk variables (2001) (0)
- Coronary artero-venous gradient of endogenous urokinase. (2001) (0)
- Effects of low-dose ethinylestradiol oral contraceptives differing in progestogen compound on coagulation- and fibrinolytic-risk variables for venous and arterial thromboembolytic diseases (1995) (0)
- O-36: Similarities in the rate of induction of changes in hemostasis variables by a transdermal contraceptive patch (ORTHO EVRA®) vs oral contraceptives in healthy female subjects (2006) (0)
- Plasminogen activation in unstable angina is associated with an acute phase response but not with activation of the hemostastic system (1996) (0)
- Genetics of Dizygotic Twinning Design and Sample Collection: A Feasability Study - Session: Current Developments and Findings from Twin Studies (2004) (0)
- EVIDENCE FOR PLASMIN-MEDIATED FIBRINOLYSIS AFTER /RELEASE OF TISSUE PLASMINOGEN ACTIVATOR BY DESMOPRESSIN INFUSION (1987) (0)
- [Plasmin-mediated activation of the coagulation system. A study of patients with acute ischemic heart disease treated with recombinant tissue-plasminogen activator]. (1994) (0)
- Act ivated protein C response and cardiovascular risk factors in the e l d e r l y . The Rotterdam Study (0)
- Leiden Fibrinolysis Workshop 6 : fibrinolysis and genetics, April 18-19, 1996, Leiden, The Netherlands (1996) (0)
- Streptokinase stimulates thrombin generation independent of its fibrinolytic effect via plasminogen (1994) (0)
- The effects of dietary fat and alcohol on fibrinolytic variables (1990) (0)
- Sample stability and agreement of data after storage of blood for white blood cell count and differentials (2001) (0)
- 197 The plasminogen binding form of α2-antiplasmin plays a major role in preventing fibrinogenolysis during thrombolytic therapy (1988) (0)
- Abstract 316: A Superantigen Whole Blood Challenge Test for the Quantification of Immuno-inflammation in Early Phase Drug Development (2013) (0)
- Clinical and biochemical aspects of the haemostatic balance in relation to development and prevention of cardiovascular diseases (2004) (0)
- Plasminogen activator inhibitor-1 and levels of sex hormone binding globulin in young women (2008) (0)
- The analytical performance of the Coamatic® Plasmin Inhibitor assay (2001) (0)
- World distribution of factor V Leiden mutation. (1996) (0)
- Plasminogen activator inhibitor 1 (PAI-1) and fibrinolysis: Inhibitor or marker? (1991) (0)
- The mode of action of sugammadex on coagulation. (2020) (0)
- Insulin resistance and hemostasis risk variables (1994) (0)
- Cholesterol ester transfer protein (CETP) levels in patients with suspected deep venous thrombosis (2010) (0)
- Visualization of The Procoagulant Effects of Combined Oral Contraceptives (COCs) (2018) (0)
- Standardization of Measurement of Components of the Fibrinolytic System - Introduction and Current Status (2000) (0)
- Comparison of nine different blood collection tubes for contact activation of coagulation (2017) (0)
- Haemostatic, fibrinolytic and lipid parameters in relation to the initial manifestation of coronary artery disease (1996) (0)
- Linkage of the APOE locus with ApoE plasma levels in adolescent Dutch twins is completely explained by the APOE e2/e3/e4 alleles (2002) (0)
- AN ALANINE INSERTION IN ALPHA-2-ANTIPLASMIN ENSCHEDE ABOLISHES ITS PLASMIN INHIBITORY ACTIVITY (1987) (0)
- Generation Of Factor XII-Dependent Plasminogen Activator Activity In Human Plasma Measured With A Fluorogenic Substrate (1981) (0)
- Functional mutations predisposing to arterial thrombosis (2000) (0)
- Limited co-variation of fibrin degradation products determined by different methods: a comparison of basal levels in two groups of women (2001) (0)
- Paraoxonase Met-55/Leu and Gln-192/Arg polymorphisms and the risk of mortality and fatal cardiovascular events in elderly subjects (1999) (0)
- pharmacodynamic effects of two recombinant Fvlla products in anticoagulated healthy volunteers : Po 292 (2013) (0)
- Does reducing a patient's CRP levels with statin therapy reduce their risk of recurrent cardiovascular events? (2005) (0)
- A New Pharmacodynamic Test to Evaluate Effects of Oral Contraceptives on Coagulation (2021) (0)
- Congenital Heterozygous azAntiplasmin Deficiency (2005) (0)
- The Contribution of the Functional IL6R Polymorphism rs2228145, eQTLs and Other Genome-Wide SNPs to the Heritability of Plasma sIL-6R Levels (2014) (0)
- Nocturnal Rise in Fibrinolytic Inhibition in Relation to the Peak Time of Onset of Thrombotic Cardiovascular Events (1988) (0)
- Effects of Low-Dose Ethinylestradiol Oral Contraceptives Differing in Progestogen Compound on Coagulation- and Fibrinolytic-Risk Variables for Venous and Arterial Thromboembolic Diseases (2019) (0)
- CHANGES IN t-PA ACTIVITY AND INHIBITION AS PART OF THE ACUTE PHASE REACTION IN ACUTE MYOCARDIAL INFARCTION (1987) (0)
- Liposomal targeting of peptides and proteins (1996) (0)
- Pro-inflammatory effects of oestrogens during use of combined oral contraceptives and oestrogen replacement treatment (2001) (0)
- Alcohol, Coagulation, and Fibrinolysis (2000) (0)
- 179. Effect of a 6 months training programme on fibrinogen and PAI1-ag in elderly people (1996) (0)
- 28 Plasmin inhibitor activity (previously u2-antiplasmin) (1999) (0)
- ID: 203 The Effects of Oral Contraceptives on Plasma - Studied by Proteomics. (2006) (0)
- Early Thrombolysis in Acute Myocardial Infarction is Associated with Reduced Plasminogen Activator Inhibitor-1 (1989) (0)
- Increased elastase degradation products of fibrinogen in stroke patients (2008) (0)
- 329 Modified crossed immunoelectrophoresis with whole plasma to study reversible complex formation of proteins of the fibrinolytic cascade (1988) (0)
- Hyperglycemia, hyperinsulinemia and inflammation in type II diabetics are associated with specific deviations in haemostatic variables (1999) (0)
- Author and Subject Index (1998) (0)
- Integrative multi-omics analysis of epigenomic and metabolomic data for attention-deficit/hyperactivity disorder (2020) (0)
- Plasmin inhibitor activity (previously α2-antiplasmin) (1999) (0)
- Abstract Poster presentation II-6: Pathophysiological studyModerate alcohol consumption has large postprandial effects on fibrinolytic factors and lipoprotein metabolism (1994) (0)
- Normal circadian variations in fibrinolysis variables (1990) (0)
- RESULTS OF A DUTCH QUESTIONNAIRE ON HAEMOSTASIS IN GASTRO-ENTEROLOGY AND LIVER DISEASE. Part I: Liver disease (1988) (0)
- No evidence for a locus influencing Lp(a) levels on chromosome 1 (2002) (0)
- RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR - PHARMACOKINETICS AND INTERACTION WITH THE FIBRINOLYTIC SYSTEM (1988) (0)
- T-pa polymorphism and use thereof in diagnosis of risk of thrombus associated disease (1997) (0)
- Author and Subject Index (1998) (0)
- Inflammatory markers as predictors in unstable angina (abstract) (1996) (0)
- Plasmin-antiplasmin complexes in prognostic evaluation of patients with unstable angina (1994) (0)
- Inter-Laboratory Variation and the Effect of the Type of Fluorimeter on the Results of the Technothrombin® Thrombin Generation Assay. (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Cornelis Kluft?
Cornelis Kluft is affiliated with the following schools:
